Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$11.66 +4.8%	$9.23	$4.88 ▼ $19.58	$252.98M	N/A	105,033 shs	36,701 shs
ATXS Astria Therapeutics	$4.96 +3.8%	$4.53	$3.56 ▼ $12.92	$279.91M	0.45	373,949 shs	456,271 shs
SLRN Acelyrin	$2.27	$2.32	$1.85 ▼ $7.25	$229.17M	1.07	1.24 million shs	N/A
VICP Vicapsys Life Sciences	$1.77	$1.77	$1.25 ▼ $3.00	$57.30M	-4.03	250 shs	N/A

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	+5.80%	+6.00%	-13.45%	-7.25%	+1,112,999,900.00%
ATXS Astria Therapeutics	+3.02%	+21.94%	-10.82%	-23.03%	-49.52%
SLRN Acelyrin	0.00%	0.00%	-11.67%	-9.20%	-44.90%
VICP Vicapsys Life Sciences	0.00%	0.00%	0.00%	-13.66%	+298.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	1.7268 of 5 stars	3.6	1.0	0.0	0.0	2.2	1.7	0.0
SLRN Acelyrin	3.5776 of 5 stars	3.2	4.0	0.0	0.0	3.3	3.3	1.3
VICP Vicapsys Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	168.01% Upside
ATXS Astria Therapeutics	3.25	Buy	$30.00	504.84% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside
VICP Vicapsys Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VICP, SLRN, AARD, and ATXS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/14/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$47.00 ➝ $47.00
4/29/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$47.00
4/1/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
4/1/2025	AARD Aardvark Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00
3/27/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
3/12/2025	ATXS Astria Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00 ➝ $28.00
3/11/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/10/2025	AARD Aardvark Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$29.00
3/10/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.33 per share	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
VICP Vicapsys Life Sciences	N/A	N/A	N/A	N/A	($0.06) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	-$72.89M	-$1.87	N/A	N/A	N/A	N/A	-43.58%	-29.36%	8/11/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)
VICP Vicapsys Life Sciences	-$1.18M	-$0.04	N/A	∞	N/A	N/A	N/A	-3,906.36%	N/A

Latest VICP, SLRN, AARD, and ATXS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
3/19/2025	Q4 2024	SLRN Acelyrin	-$0.86	-$0.79	+$0.07	-$0.79	N/A	N/A
3/11/2025	Q4 2024	ATXS Astria Therapeutics	-$0.45	-$0.44	+$0.01	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
VICP Vicapsys Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	N/A	N/A
ATXS Astria Therapeutics	N/A	22.38	22.38
SLRN Acelyrin	N/A	7.15	7.15
VICP Vicapsys Life Sciences	N/A	0.03	0.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ATXS Astria Therapeutics	98.98%
SLRN Acelyrin	87.31%
VICP Vicapsys Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
ATXS Astria Therapeutics	2.90%
SLRN Acelyrin	13.60%
VICP Vicapsys Life Sciences	5.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
ATXS Astria Therapeutics	30	56.43 million	54.80 million	Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable
VICP Vicapsys Life Sciences	2	32.37 million	30.44 million	Not Optionable

VICP, SLRN, AARD, and ATXS Headlines

Recent News About These Companies

British Science Week - Teaching Resources

November 6, 2024 | bbc.co.uk

Best term life insurance: Expert-rated in April 2024

April 28, 2024 | usatoday.com

Scanning Electron Microscopy for the Life Sciences

April 20, 2024 | cambridge.org

EY Life Sciences

April 8, 2024 | pmlive.com

Life Science

January 30, 2024 | dmagazine.com

Caris Life Sciences

November 30, 2023 | dmagazine.com

Anavex Life Sciences Corp AVXL

November 4, 2023 | morningstar.com

VICP - Vicapsys Life Sciences, Inc.

August 9, 2023 | finance.yahoo.com

ViCapsys files for Nasdaq uplisting, $8M public offering

July 3, 2023 | msn.com

Life sciences sector to get £650m boost in new Government funding package

June 9, 2023 | aol.co.uk

‘Not Seeing Any Activity At All’: Once-Hot Life Sciences Leasing Market Freezes

April 1, 2023 | bisnow.com

The Science of Life

March 29, 2023 | nature.com

The ultimate list of leaders in life sciences.

March 16, 2023 | statnews.com

Defining life and personhood: What science, philosophy, and religion have to say

March 13, 2023 | kcrw.com

Life Sciences Innovator Category Winner 2023

February 23, 2023 | news-medical.net

Global law firm Goodwin is setting up a Philly tech, startups and life sciences practice

February 21, 2023 | technical.ly

Global Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market Prospects

February 19, 2023 | benzinga.com

Focused exclusively on life sciences, three top investors set out on their own

January 28, 2023 | statnews.com

Top risks for life sciences sector revealed – report

January 15, 2023 | canadianlawyermag.com

Houston On Track As Future Life Sciences Powerhouse, But Everyone Needs To Mind The Gaps First

January 15, 2023 | bisnow.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VICP, SLRN, AARD, and ATXS Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$11.66 +0.53 (+4.76%)

As of 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Astria Therapeutics NASDAQ:ATXS

$4.96 +0.18 (+3.77%)

Closing price 04:00 PM Eastern

Extended Trading

$4.97 +0.01 (+0.28%)

As of 04:56 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Acelyrin NASDAQ:SLRN

$2.27 0.00 (0.00%)

As of 05/21/2025

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Vicapsys Life Sciences OTCMKTS:VICP

$1.77 0.00 (0.00%)

As of 06/2/2025

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time